Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 14, 2023 07:00 ET | Source: Alvotech

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)

PrJamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. REYKJAVIK, Iceland and BOUCHERVILLE, Quebec, Nov. 14, 2023 (GLOBE NEWSWIRE) --...
November 14, 2023 07:00 ET | Source: Alvotech

Alvotech og JAMP Pharma hljóta markaðsleyfi í Kanada fyrir Jamteki, líftæknilyfjahliðstæðu við Stelara

Jamteki (AVT04) er önnur líftæknilyfjahliðstæðan sem samstarfsfélögin setja á markað í Kanada Alvotech (NASDAQ: ALVO) og JAMP Pharma Group („JAMP Pharma“) tilkynntu í dag Heilbrigðisstofnun Kanada,...
November 14, 2023 07:00 ET | Source: Alvotech

Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki (AVT04), the First Biosimilar of Stelara® (ustekinumab)

JamtekiTM is the second biosimilar developed under this partnership that receives marketing authorization in Canada. Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development...
November 10, 2023 09:30 ET | Source: Alvotech

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...
November 10, 2023 09:30 ET | Source: Alvotech

Alvotech og STADA fyrst til að hljóta jákvæða afgreiðslu lyfjastofnunar Evrópu á umsókn um markaðsleyfi fyrir líftæknilyfjahliðstæðu við Stelara

Jákvæðri umsögn lyfjanefndarinnar verður vísað til framkvæmdastjórnar ESB sem tekur ákvörðun um veitingu markaðsleyfis á Evrópska efnahagssvæðinuTekjur af sölu Stelara í Evrópu nema um 380 milljörðum...
November 10, 2023 09:30 ET | Source: Alvotech

STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara

CHMP positive opinion in the European Economic Area for first biosimilar to Stelara, a biologic therapy within gastroenterology, dermatology and rheumatologyPositive CHMP opinion for Uzpruvo...
November 07, 2023 08:00 ET | Source: Alvotech

Alvotech tekur þátt í heilbrigðisráðstefnu Jefferies í London

Alvotech (NASDAQ: ALVO) tekur þátt í heilbrigðisráðstefnu fjárfestingabankans Jefferies, sem haldin verður í London dagana 14.- 16. nóvember n.k. Stjórnendur Alvotech munu þar kynna starfsemi...
November 07, 2023 08:00 ET | Source: Alvotech

Alvotech to Present at the Jefferies 2023 London Healthcare Conference

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies...
November 07, 2023 08:00 ET | Source: Alvotech

Alvotech to Present at the Jefferies 2023 London Healthcare Conference

REYKJAVIK, Iceland, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
October 12, 2023 04:00 ET | Source: Alvotech

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that the US Food and Drug...